13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002054410
Total reported value
$366.5M
$366.5M
20 檔
34.7%
The Q3 2025 SEC filing reveals that Acorn Capital Advisors, LLC held a total portfolio value of $366.5M, covering 20 public equity positions.
Acorn Capital Advisors, LLC executed strategic sector rebalancing during Q3 2025, establishing 1 new positions while fully exiting 3 holdings and trimming 3 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 23.14% | +0.17% | — | |
| 2 | URGN | UroGen Pharma Ltd. | Stock-Other | 12.76% | +8.25% | — | |
| 3 | PBYI | Puma Biotechnology Inc | Stock-Other | 11.14% | +1.64% | — | |
| 4 | TRVI | Trevi Therapeutics Inc | Stock-Other | 9.96% | +3.65% | — | |
| 5 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 7.52% | -26.17% | EXIT | |
| 6 | CADL | Candel Therapeutics Inc | Stock-Other | 6.68% | +4.94% | — | |
| 7 | BCAX | Bicara Therapeutics Inc | Stock-Other | 5.16% | +1.57% | — | |
| 8 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 3.96% | +0.19% | — | |
| 9 | TARA | Protara Therapeutic Inc | Stock-Other | 3.87% | -0.76% | — | |
| 10 | VSTM | Verastem Inc | Stock-Other | 3.49% | -0.68% | — | |
| 11 | HELP | Cybin Inc | Stock-Other | 2.19% | +0.68% | — | |
| 12 | CRDF | Cardiff Oncology Inc | Stock-Other | 2.05% | -0.81% | EXIT | |
| 13 | AURA | Aura Biosciences Inc | Stock-Other | 1.87% | +0.67% | — | |
| 14 | BCABGBP | Bioatla Inc | Stock-Other | 1.69% | -0.13% | — | |
| 15 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.67% | -0.19% | — | |
| 16 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 1.10% | +0.30% | — | |
| 17 | QTTB | Q32 Bio Inc | Stock-Other | 0.81% | +0.18% | — | |
| 18 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 0.47% | -0.27% | EXIT | |
| 19 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.37% | — | — | |
| 20 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.10% | — | -20.36% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | +4.7% | — | Unchanged |
| 2 | 430 | Terns Pharmaceuticals Inc | +3.9% | — | Unchanged |
| 3 | PBYI | Puma Biotechnology Inc | +3.4% | — | Add |
| 4 | URGN | UroGen Pharma Ltd. | +1.6% | — | Trim |
| 5 | TRVI | Trevi Therapeutics Inc | +1% | — | Unchanged |
| 6 | AURA | Aura Biosciences Inc | +0.9% | — | Add |
| 7 | BCABGBP | Bioatla Inc | +0.8% | — | Add |
| 8 | OKUR | Onkure Therapeutics Inc-a | +0.5% | — | Add |
| 9 | VSTM | Verastem Inc | +0.4% | — | Unchanged |
| 10 | TARA | Protara Therapeutic Inc | +0.2% | — | Add |
| 11 | QTTB | Q32 Bio Inc | -0.1% | — | Unchanged |
| 12 | ACRV | Acrivon Therapeutics Inc | -0.2% | — | Unchanged |
| 13 | WHWK | Whitehawk Therapeutics Inc | -0.3% | — | Unchanged |
| 14 | BCAX | Bicara Therapeutics Inc | -0.4% | — | Unchanged |
| 15 | ASNSUSD | X4 Pharmaceuticals Inc | -0.7% | +77.81% | Trim |
| 16 | VYNE | Vyne Therapeutics Inc | -0.7% | -20.36% | Trim |
| 17 | HELP | Cybin Inc | -0.9% | — | Unchanged |
| 18 | CRDF | Cardiff Oncology Inc | -1% | +39.28% | Add |
| 19 | CADL | Candel Therapeutics Inc | -1.4% | — | Add |
| 20 | YMABUSD | Y-mabs Therapeutics Inc | — | EXIT | Sold out |
| 21 | OPTNUSD | Optinose Inc | — | EXIT | Sold out |
| 22 | JSPR | Jasper Therapeutics Inc | — | NEW | New buy |
| 23 | ✓ | Mural Oncology Pub LTD Co | — | EXIT | Sold out |
According to official SEC Form 13F filings, Acorn Capital Advisors, LLC reported a total U.S. public equity portfolio value of $366.5M across 20 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CGON, URGN, PBYI) accounted for 34.7% of total reported equity market value during Q3 2025.
Top New Position Initiated
JSPR
市值: $3.3M
Top Position Liquidated / Trimmed
YMABUSD
前期市值: $14.3M
During Q3 2025, Acorn Capital Advisors, LLC's top holdings by market value included CGON (23.1%)、URGN (12.8%)、PBYI (11.1%). The largest single position, CGON, represented 23.1% of total portfolio value.
In Q3 2025, Acorn Capital Advisors, LLC made 14 total portfolio adjustments, initiating 1 new buys, adding to 7 positions, trimming 3 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.